Butrans, Sublocade, Buvidal, Sixmo (buprenorphine) is a small molecule pharmaceutical. Buprenorphine was first approved as Butrans on 2010-06-30. It is used to treat heroin dependence and pain in the USA. It has been approved in Europe to treat opioid-related disorders. The pharmaceutical is active against mu-type opioid receptor and kappa-type opioid receptor. Buprenorphine hcl's patents are valid until 2038-06-22 (FDA).
|Trade Name||Buvidal, Sixmo|
|Indication||heroin dependence, opioid-related disorders, pain|